In addition to private company investments, Abingworth aims to invest in undervalued public companies that have the potential to provide venture capital-like returns. The company uses its networks, financial expertise and industry knowledge to select firms with experienced management and products or technology with significant commercial potential. As of September 2007, Abingworth had public market funds under management of over $400 million.

Abingworth BioEquities (ABE) is an open-ended fund, launched in July 2005, that invests only in quoted life science companies. ABE’s strategy is to invest globally in under-appreciated public life science companies that have the potential to deliver high returns over a two to four year investment period.